Early rectal cancer beyond the reach of conventional instruments has resulted in major abdominal and pelvic operations. As visualization is compromised beyond 6 - 8 cm, proximal to the anal verge, there have been several innovations and techniques to address T1 or T2 rectal cancer in the mid to upper rectum. Transanal Endscopic Microsurgery (TEM) was a technique that had garnered some success, however with expensive instrumentation along with limitations in instrument mobility, this technology was not applicable to many patients. Transanal Endoscopic Video Assisted (TEVA) rectal resection offers a cheap and readily accessible media to address early rectal cancer. Any hospital with standard laparoscopic ability is capable to offer TEVA rectal resection. We do advocate appropriate patient selection and advise that there is a learning curve with the increased requirement for technical difficulty. Once mastered, however, this surgical approach does provide yet another tool in the armamentarium of the surgeon.
Lesions in the mid to distal rectum have often required a formal oncologic resection. While this has been technically feasible, it does preclude a certain mobidity, including bleeding and nerve damage particularly in reference to the pelvic anatomy. Lesions that are not amenable to endoscopic removal must be resected, however, until recently there were not many alternatives available except for major abdominal and pelvic surgery.
Transanal Endoscopic Video Assisted (TEVA) rectal lesion excision offers a different avenue to address rectal masses. This technique offers a full thickness rectal excision without an abdominal operation or pelvic dissection. There does exist a very strict criteria of patient selection before TEVA procedures can be offered to the patient:
1) Rectal lesions must be benign or early stage adenocarcinoma not more than (uT1N0);
2) The anatomical location of the rectal lesion must not extend beyond 10 cm proximally or 5 cm distally;
3) Lesions must not encompass greater than 40% of the intraluminal rectal wall.
These criteria ensure maximal success from our experience.
Patients are placed in lithotomy position irrespective of the lesion location or orientation. A SILSTM (Covidien, Mansfield, MA) port is introduced into the rectum and secured in place (
Following sustained rectal distension with carbon dioxide, the rectal lesion is identified and the outer mucosal margins are marked using electrocautery in a circumferential manner (
lesion is completely excised, the port is removed to facilitate extraction, however great care is used to ensure that the orientation of the specimen is maintained. The specimen is marked and orientated for pathology.
The rectal defect can be closed using the SILS port. Standard laparoscopic suture technique is technically feasible yet meticulous. The authors have used the V-LOC (Covidien, Mansfield, MA) closure device to aid in the closure of the defect (
Wile TEVA rectal lesion resection offers excellent visualization and approach to mid rectal lesions we underscore the importance of pre-operative patient selection. Lesions T2 or advanced should undergo a formal oncologic resection with total mesorectal excision (TME), particularly with their associated high rate of recurrence and lymph node invlolvement [1,2]. Although it has been reported that T2 lesions can be locally resected with adjuvant chemotherapy, and yield favorable results, we prefer formal oncologic resection with TME for these cancers, when feasible [3-5]. The applicability of this newer technology and technique is aimed primarily at early rectal cancer lesions that are beyond the reach of a standard transanal approach, however are amenable to local excision. Prior to TEVA, early rectal cancer that was not able to be removed via the transanal approach required a major pelvic dissection. TEVA resection offers a method to remove these mid rectal lesions with most patients discharged home the same day of the procedure. It is yet
one more tool in the armamentarium of the surgeon addressing rectal cancer.